E

Editas Medicine
D

EDIT

1.34500
USD
-0.18
(-11.51%)
مغلق
حجم التداول
103,032
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
111,027,193
أصول ذات صلة
    ALNY
    ALNY
    -8.630
    (-3.50%)
    237.920 USD
    B
    BEAM
    -2.140
    (-7.49%)
    26.440 USD
    B
    BLUE
    -0.51500
    (-5.75%)
    8.44000 USD
    C
    CRSP
    -3.490
    (-7.83%)
    41.110 USD
    N
    NTLA
    -1.110
    (-8.45%)
    12.020 USD
    R
    RGEN
    -11.120
    (-7.02%)
    147.190 USD
    S
    SGMO
    -0.48000
    (-17.02%)
    2.34000 USD
    TMO
    TMO
    -12.62
    (-2.39%)
    516.10 USD
    VRTX
    VRTX
    -21.90
    (-4.67%)
    447.46 USD
    المزيد
الأخبار

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.